Blueprint Medicines (BPMC) Tops Q3 EPS by $3.50

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of $11.16, $3.50 better than the analyst estimate of $7.66. Revenue for the quarter came in at $745.1 million versus the consensus estimate of $628.68 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• Kaiser Aluminum (KALU) Tops Q1 EPS by 42c
• Universal Health Realty (UHT) Reports Q1 EPS of $0.38